Advanced search
Publication Cover
Expert Review of Respiratory Medicine Volume 6, 2012 - Issue 3
Submit an article Journal homepage
127
Views
9
CrossRef citations to date
0
Altmetric
Review

Future of chronic obstructive pulmonary disease management

Anthony D'Urzo Department of Family and Community Medicine (DFCM), University of Toronto, ON, Canada. [email protected]; Department of Family and Community Medicine (DFCM), University of Toronto, ON, Canada. [email protected]
&
Claus Vogelmeier Department of Respiratory Medicine, University of Marburg, Marburg, Germany; Department of Respiratory Medicine, University of Marburg, Marburg, Germany
Pages 285-299 | Published online: 09 Jan 2014

References

  • Postma D, Anzueto A, Calverley P et al. A new perspective on optimal care for patients with COPD. Prim. Care Respir. J. 20(2), 205–209 (2011).
  • Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur. Respir. J. 23(6), 932–946 (2004).
  • Cazzola M, Matera MG. Long-acting bronchodilators are the first-choice option for the treatment of stable COPD. Chest 125(1), 9–11 (2004).
  • Cazzola M, Matera MG. Emerging inhaled bronchodilators: an update. Eur. Respir. J. 34(3), 757–769 (2009).
  • Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin. Ther. 23(8), 1296–1310 (2001).
  • Campbell M, Eliraz A, Johansson G et al. Formoterol for maintenance and as needed treatment of chronic obstructive pulmonary disease. Respir. Med. 99(12), 1511–1520 (2005).
  • Mahler DA, Donohue JF, Barbee RA et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 115(4), 957–965 (1999).
  • Ramirez-Venegas A, Ward J, Lentine T, Mahler DA. Salmeterol reduces dyspnea and improves lung function in patients with COPD. Chest 112(2), 336–340 (1997).
  • Boyd G, Morice AH, Pounsford JC, Siebert M, Peslis N, Crawford C. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur. Respir. J. 10(4), 815–821 (1997).
  • Cazzola M, Matera MG, Santangelo G, Vinciguerra A, Rossi F, D’Amato G. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose–response study. Respir. Med. 89(5), 357–362 (1995).
  • Sin DD, McAlister FA, Man SF, Anthonisen NR. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA 290(17), 2301–2312 (2003).
  • Rodrigo GJ, Nannini LJ, Rodríguez-Roisin R. Safety of long-acting beta-agonists in stable COPD: a systematic review. Chest 133(5), 1079–1087 (2008).
  • Dahl R, Kolman P, Jack D et al. Efficacy of a new once-daily LABA, indacaterol, versus the twice-daily LABA, formoterol, in COPD. Thorax 65, 473–479 (2010).
  • Donohue JF, Fogarty C, Lotvall J et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol vs. tiotropium. Am. J. Respir. Crit. Care Med. 182(2), 155–162 (2010).
  • Feldman G, Siler T, Pasad N et al. Efficacy and safety of indacaterol 150 µg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm. Med. 10(1), 11 (2010).
  • Kornmann O, Luthra A, Owen R, Lassen C, Kramer B. Once-daily indacaterol vs twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur. Respir. J. 37(2), 273–279 (2010).
  • LaForce C, Janssens E, de Teresa Parreño L et al. Sustained 24-h efficacy of once daily indacaterol (300 μg) in patients with chronic obstructive pulmonary disease: a randomized, crossover study. Pulm. Pharmacol. Ther. 24(1), 162–168 (2011).
  • Balint B, Watz H, Amos C, Owen R, Higgins M, Kramer B; INSURE Study Investigators. Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol–fluticasone. Int. J. Chron. Obstruct. Pulmon. Dis. 5, 311–318 (2010).
  • Beeh KM, Wagner F, Khindri S, Drollmann AF. Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD. COPD 8(5), 340–345 (2011).
  • Magnussen H, Verkindre C, Jack D et al.; INPUT study investigators. Indacaterol once-daily is equally effective dosed in the evening or morning in COPD. Respir. Med. 104(12), 1869–1876 (2010).
  • Vogelmeier C, Ramos-Barbon D, Jack D et al.; INTIME study investigators (Indacaterol & Tiotropium: Measuring Efficacy). Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium. Respir. Res. 11, 135 (2010).
  • Chapman KR, Rennard SI, Dogra A, Owen R, Lassen C, Kramer B; INDORSE Study Investigators. Long-term safety and efficacy of indacaterol, a long-acting β2-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest 140(1), 68–75 (2011).
  • Buhl R, Dunn LJ, Disdier C et al.; INTENSITY study investigators. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur. Respir. J. 38(4), 797–803 (2011).
  • O’Donnell DE, Casaburi R, Vincken W et al.; INABLE 1 study group. Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respir. Med. 105(7), 1030–1036 (2011).
  • Casaburi R, Mahler DA, Jones PW et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. 19(2), 217–224 (2002).
  • Donohue J, van Noord JA, Bateman ED et al. A 6-month placebo controlled study comparing lung function and health status changes in COPD patients treated with tiotropium of salmeterol. Chest 122, 47–55 (2002).
  • Celli B, ZuWallack R, Wang S, Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 124(5), 1743–1748 (2003).
  • Tashkin DP, Celli B, Senn S et al.; UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 359(15), 1543–1554 (2008).
  • O’Donnell DE, Flüge T, Gerken F et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur. Respir. J. 23(6), 832–840 (2004).
  • Niewoehner DE, Rice K, Cote C et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann. Intern. Med. 143(5), 317–326 (2005).
  • Rabe KF, Bateman ED, O’Donnell D, Witte S, Bredenbröker D, Bethke TD. Roflumilast – an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 366(9485), 563–571 (2005).
  • Calverley PM, Sanchez-Toril F, McIvor A, Teichmann P, Bredenbroeker D, Fabbri LM. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 176(2), 154–161 (2007).
  • Rennard SI, Calverley PMA, Goehring UM, Bredenbroker D, Martinez FJ. Reduction of exacerbations by the PDE4 inhibitor roflumilast–the importance of defining different subsets of patients with COPD. Respir. Res. 12, 18 (2011).
  • Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ; M2-124 and M2-125 study groups. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 374(9691), 685–694 (2009).
  • Fabbri LM, Calverley PM, Izquierdo-Alonso JL et al.; M2-127 and M2-128 study groups. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 374(9691), 695–703 (2009).
  • Cazzola M. The divergent opinions of regulatory authorities on roflumilast are puzzling but we need new drugs for treating chronic obstructive pulmonary disease. Ther. Adv. Respir. Dis. 4(4), 195–198 (2010).
  • Price D, Chisholm A, Ryan D, Crockett A, Jones R. The use of roflumilast in COPD: a primary care perspective. Prim. Care Respir. J. 19(4), 342–351 (2010).
  • Tashkin D, Celli B, Decramer M et al. Prescribing patterns according to COPD treatment guidelines in patients enrolled in a global clinical trial. Proc. Am. Thorac. Soc. 3, A111 (2006).
  • Hanania NA, Darken P, Horstman D et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest 124(3), 834–843 (2003).
  • Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur. Respir. J. 22(6), 912–919 (2003).
  • Calverley PM, Anderson JA, Celli B et al.; TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 356(8), 775–789 (2007).
  • Um SW, Yoo CG, Kim YW, Han SK, Shim YS. The combination of tiotropium and budesonide in the treatment of chronic obstructive pulmonary disease. J. Korean Med. Sci. 22(5), 839–845 (2007).
  • Choi J, Na J, Kim Y. The effect of tiotropium and inhaled corticosteroid combination therapy in chronic obstructive pulmonary disease and chronic bronchial asthma associated with irreversible pulmonary function. Am. J. Respir. Crit. Care Med. 175, A130 (2007).
  • Cazzola M, Molimard M. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. Pulm. Pharmacol. Ther. 23(4), 257–267 (2010).
  • Roux E, Molimard M, Savineau JP, Marthan R. Muscarinic stimulation of airway smooth muscle cells. Gen. Pharmacol. 31(3), 349–356 (1998).
  • Cazzola M, Di Marco F, Santus P et al. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm. Pharmacol. Ther. 17(1), 35–39 (2004).
  • Cazzola M, Centanni S, Santus P et al. The functional impact of adding salmeterol and tiotropium in patients with stable COPD. Respir. Med. 98(12), 1214–1221 (2004).
  • van Noord JA, Aumann JL, Janssens E et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur. Respir. J. 26(2), 214–222 (2005).
  • van Noord JA, Aumann JL, Janssens E et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 129(3), 509–517 (2006).
  • Rabe KF, Timmer W, Sagkriotis A, Viel K. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest 134(2), 255–262 (2008).
  • Tashkin DP, Donohue JF, Mahler DA et al. Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD. Respir. Med. 103(4), 516–524 (2009).
  • Mahler DA, D’Urzo A, Peckitt C et al. Combining once-daily bronchodilators in COPD: indacaterol plus tiotropium versus tiotropium alone. Am. J. Respir. Crit. Care Med. 183, A1591 (2011).
  • Bouyssou T, Casarosa P, Naline E et al. Pharmacologic characterization of olodaterol, a novel inhaled beta2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models. J. Pharmacol. Exp. Ther. 334, 53–62 (2010).
  • O’Byrne PM, van der Linde J, Cockcroft DW et al. Prolonged bronchoprotection against inhaled methacholine by inhaled BI 1744, a long-acting beta(2)-agonist, in patients with mild asthma. J. Allergy Clin. Immunol. 124(6), 1217–1221 (2009).
  • van Noord J, Korducki L, Hamilton A, Koker P. Four weeks once-daily treatment with BI 1744 CL, a novel long-acting b2-agonist, is effective in COPD patients. Am. J. Respir. Crit. Care Med. 179, A6183 (2009).
  • van Noord JA, Smeets JJ, Drenth BM et al. 24-hour bronchodilation following a single dose of the novel β(2)-agonist olodaterol in COPD. Pulm. Pharmacol. Ther. 24(6), 666–672 (2011).
  • Cazzola M, Calzetta L, Matera MG. Beta(2)-adrenoceptor agonists: current and future direction. Br. J. Pharmacol. 163, 4–17 (2011).
  • Kempsford R, Norris V, Siederer S. GW642444, a novel inhaled long-acting Beta2 adrenoceptor agonist (LABA), at single doses of 25, 50 and 100mcg, is well tolerated and demonstrates prolonged bronchodilation in COPD patients. Am. J. Respir. Crit. Care Med. 181, A4447 (2010).
  • Hanania NA, Feldman G, Zachgo W et al. The efficacy and safety of the novel long-acting β2 agonist vilanterol in COPD patients: a randomized placebo-controlled trial. Chest doi:10.1378/chest.11-2231 (2012) (Epub ahead of print).
  • Beeh KM, Welte T, Buhl R. Anticholinergics in the treatment of chronic obstructive pulmonary disease. Respiration 69(4), 372–379 (2002).
  • Abrams P, Andersson KE, Buccafusco JJ et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br. J. Pharmacol. 148(5), 565–578 (2006).
  • Vogelmeier C, Banerji D. NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary disease. Ther. Adv. Respir. Dis. 5(3), 163–173 (2011).
  • Gavaldà A, Miralpeix M, Ramos I et al. Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile. J. Pharmacol. Exp. Ther. 331(2), 740–751 (2009).
  • Cortijo J, Mata M, Milara J et al. Aclidinium inhibits cholinergic and tobacco smoke-induced MUC5AC in human airways. Eur. Respir. J. 37(2), 244–254 (2011).
  • Sentellas S, Ramos I, Albertí J et al. Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacologic activity of its main metabolites. Eur. J. Pharm. Sci. 39(5), 283–290 (2010).
  • Chanez P, Burge PS, Dahl R et al. Aclidinium bromide provides long-acting bronchodilation in patients with COPD. Pulm. Pharmacol. Ther. 23(1), 15–21 (2010).
  • Joos GF, Schelfhout VJ, Pauwels RA et al. Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients. Respir. Med. 104(6), 865–872 (2010).
  • Fuhr R, Magnussen H, Sarem K et al. Efficacy of aclidinium bromide 400 µg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD. Chest 141(3), 745–752 (2012).
  • Jones PW, Agusti A, Bateman ED et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: efficacy and safety results from ATTAIN. Am. J. Respir. Crit. Care Med. 183, A6350 (2011).
  • Kerwin EM, D’Urzo AD, Gelb AF, Lakkis H, Garcia Gil E, Caracta CF; ACCORD I study investigators. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD 9(2), 90–101 (2012).
  • Maltais F, Celli B, Casaburi R et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respir. Med. 105(4), 580–587 (2011).
  • Kerwin EM, Rennard SI, Gelb AF et al. Twice-daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in Accord COPD I. Am. J. Respir. Crit. Care Med. 183, A1592 (2011).
  • D’Urzo A, Make BJ, Kerwin EM et al. Safety and tolerability of twice daily aclidinium bromide in COPD patients: ACCORD COPD I. Am. J. Respir. Crit. Care Med. 183, A1614 (2011).
  • Decramer M, Maltais F, Feldman G et al. Dose-related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation, in COPD. Eur. Respir. J. 38, 150s (2011).
  • Donohue JF, Anzueto A, Brooks J et al. Dose-related efficacy of GSK573719, a long-acting muscarinic receptor antagonist (LAMA) with sustained 24-hour activity, in COPD. Chest 140, 1043A (2011).
  • Reisner C, Orevillo C, St Rose E et al. Dose- and exposure response analysis of glycopyrrolate (GP) metered dose inhaler (MDI) to support optimal dosing in patients with COPD for combination product development. Eur. Respir. J. 36(Suppl. 54), P4538 (2010).
  • Rennard SI, Fogarty C, Ferguson GT et al. A novel nlycopyrrolate netered dose inhaler formulation demonstrates superior bronchodilator efficacy relative to placebo and comparable efficacy and safety to spiriva® handihaler® in patients with COPD. Am. J. Respir. Crit. Care Med. 181, A4450 (2010).
  • Orevillo C, St Rose E, Strom S et al. Glycopyrrolate MDI demonstrates comparable efficacy and safety to tiotropium DPI in a randomized, double-blind, placebo-controlled Phase 2b study in patients with COPD. Eur. Respir. J. 38(Suppl. 55), P3975 (2011).
  • Haddad EB, Patel H, Keeling JE et al. Pharmacologic characterization of the muscarinic receptor antagonist, glycopyrrolate, in human and guinea-pig airways. Br. J. Pharmacol. 127, 413–420 (1999).
  • Trifilieff A, Cope N, Bohacek B, Mazzoni L, Collingwood S. The inhaled antimuscarinic receptor antagonist, NVA237 (glycopyrrolate), has a favorable side-effect profile in a Brown Norway rat lung function model when compared with tiotropium. Chest 132, 530a (2007).
  • Cooper N, Walker I, Knowles I. NVA237 has similar efficacy as tiotropium bromide against methacholine-induced bronchoconstriction and less systemic effect on cardiovascular variables in an anaesthetized rabbit model. Eur. Respir. J. 28(Suppl. 50), P2544 (2006).
  • Fogarty C, Hattersley H, Di Scala L, Drollmann A. Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients. Respir. Med. 105(3), 337–342 (2011).
  • Verkindre C, Fukuchi Y, Flémale A et al. Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Respir. Med. 104(10), 1482–1489 (2010).
  • Vogelmeier C, Verkindre C, Cheung D et al. Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Pulm. Pharmacol. Ther. 23(5), 438–444 (2010).
  • D’Urzo A, Ferguson GT, van Noord JA et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir. Res. 12, 156 (2011).
  • Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr. Med. Res. Opin. 25(8), 2043–2048 (2009).
  • Casaburi R, Briggs DD Jr, Donohue JF, Serby CW, Menjoge SS, Witek TJ Jr. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group. Chest 118(5), 1294–1302 (2000).
  • Witek TJ Jr, Mahler DA. Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur. Respir. J. 21(2), 267–272 (2003).
  • Jones P, Lareau S, Mahler DA. Measuring the effects of COPD on the patient. Respir. Med. 99(Suppl. B), S11–S18 (2005).
  • Beeh KM, Drollmann A, Di Scala L, Smith R. Late-breaking abstract: once-daily NVA237 improves exercise endurance from first dose in patients with COPD: the GLOW3 trial. Eur. Respir. J. 38, 819s (2011).
  • Norris V, Zhu C, Ambery C. The pharmacodynamics of GSK961081 in patients with COPD. Eur. Respir. J. 38, 138s (2011).
  • Tashkin DP, Pearle J, Lezzoni D, Verghese ST. Formorterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD 6, 17–25 (2009).
  • van Noord JA, Buhl R, Laforce C et al. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax 65(12), 1086–1091 (2010).
  • Van de Maele B, Fabbri LM, Martin C et al. Cardiovascular safety of QVA149, a combination of indacaterol and NVA237, in COPD patients. COPD 7, 418–427 (2010).
  • Agustí A, Vestbo J. Current controversies and future perspectives in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 184(5), 507–513 (2011).
  • Tashkin DP, Fabbri LM. Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir. Res. 11, 149 (2010).
  • Laforest L, Denis F, Van Ganse E et al. Correlates of adherence to respiratory drugs in COPD patients. Prim. Care Respir. J. 19(2), 148–154 (2010).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.